Taysha Gene Therapies, Inc. TSHA 深 沪
交易中 08-10 10:25:36 美东时间
6.535
-0.025
-0.38%
华盛通- 最 高6.60
- 今 开6.48
- 成交量 32.29万股
- 最 低 6.30
- 昨 收 6.56
- 总市值 20.90亿
- 52周最高 7.30
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 2.7106
- 委 比 42.50%
- 总股本 3.20亿
- 历史最高 33.35
- 量 比 1.32
- 振 幅 4.57%
- 历史最低 0.50
- 每 手 1
- 风险率 1.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have entered into a commercial supply agreement for TSHA-102, a gene therapy for Rett syndrome. Catalent will serve as Taysha's primary manufacturer following potential FDA approval, leveraging its expertise in gene therapy manufacturing. This partnership aims to secure long-term commercial production capacity and scalable supply to meet future demand. Rett syndrome is a rare neurodevelopmental disorder caused b...
08-03 12:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
07-21 20:43
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.
07-13 22:24
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.
07-02 20:56
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗健康企业：HeartFlow Inc（HTFL）、Taysha Gene Therapies（TSHA）及Abivax SA赞助ADR（ABVX）
医疗保健领域近期有3位分析师分别对HTFL、TSHA、ABVX三家公司给出看涨评级。 各标的核心评级与数据如下： HTFL：Canaccord Genuit...
06-30 19:41
分析师解读医疗企业：HeartFlow, Inc.（HTFL）、Taysha Gene Therapies（TSHA）及Abivax SA保荐ADR（ABVX）
3位分析师近日先后对3只美股医疗保健标的给出看涨评级，相关标的及核心评级、数据如下： HeartFlow（HTFL）：Canaccord Genuity分析师...
06-30 19:39
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday. Shares of H.B. Fuller Company (NYSE:FUL) fell sharply in pre-market trading following second-quarter results. H.B. Fuller posted upbeat earnings for the second quarter and raised its FY2026 ear...
06-25 20:08
Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Micron Technology Inc (NASDAQ:MU) rose sharply in pre-market trading after the company posted better-than-expected financial results for the third quarter of fiscal 2026 and issued strong guidance for the current quarter. Micron reported third-quarter revenue of $41.46 billion, exceeding a...
06-25 17:08
